Michael Kirmiz, Senior Scientist, Bio-Rad Laboratories, Inc.
Presented by: Michael Kirmiz, Senior Scientist, Bio-Rad Laboratories, Inc.
Date: Session 1: March 15, 2023, at 9 AM, U.S. Pacific time
(5 PM, Central European time) Session 2: March 15, 2023, at 10 PM U.S. Pacific time
(March 16, 2023 at 1 PM, Singapore time)

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows. Nonviral methods, such as electroporation, represent a potentially safer and less challenging approach for generating CAR T cells. Flexible, high throughput technologies such as flow cytometry can greatly assist in reducing the challenges of CAR-T workflows.

In this webinar, we describe the generation of anti-CD19 CAR T cells in an mRNA electroporation–based CAR T-cell workflow optimized for efficiency and viability. See how CAR transfection efficiencies as high as ~70 and ~90% in primary and immortalized human T cells, respectively, and a viability of ~60% in primary human T cells, were achieved. These data highlight the utility of the Gene Pulser Xcell Electroporation System for generating CAR T cells via mRNA electroporation and the ZE5 Cell Analyzer for expression and analysis.

Watch Webinar
Previous post

Downstream Process Development for the Purification of Biosimilar Insulin from Escherichia coli

Next post

Maximizing Metastasis Insights with a Novel Integrated Workflow for CTC Enrichment and Enumeration